Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab

被引：9

作者：

Khimani, Karima ^{[1
]}

Patel, Sapna P. ^{[2
]}

Whyte, Andrew ^{[3
]}

Al-Zubidi, Nagham ^{[3
,4
,5
]}

机构：

[1] Univ Texas Med Branch, Dept Ophthalmol, Galveston, TX 77555 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Sect Ophthalmol, Houston, TX 77030 USA

[4] Houston Methodist Hosp, Blanton Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA

[5] Weill Cornell Med, Dept Ophthalmol, New York, NY 10021 USA

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

neuromyelitis optica spectrum disorder; NMO; immune checkpoint inhibitor; ipilimumab; nivolumab; uveal melanoma; CELL LUNG-CANCER; OPEN-LABEL; CHEMOTHERAPY; PHASE-3;

D O I：

10.3389/fonc.2022.806501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of immune checkpoint inhibitors (ICIs) has greatly improved survival of patients with advanced malignancies. ICIs can cause immune-related adverse effects (irAEs) involving any organ. Neurological irAEs are infrequent and have mostly been reported in patients with melanoma. We describe the case of a 57-year-old male with right eye uveal melanoma, gene expression profile (class 2), and PRAME (preferentially expressed antigen in melanoma) positivity, who received plaque brachytherapy with Iodine-125 for 4 days with subsequent adjuvant ICIs (immune checkpoint inhibitors), nivolumab and ipilimumab. 18 weeks after discontinuation of immunotherapy, the patient presented with acute onset of left-sided headaches, pain with eye movements, and vision loss. The patient was tested positive for serum anti-aquaporin-4 antibody (AQP4-Ab) and was diagnosed with neuromyelitis optica spectrum disorder (NMOSD). Subsequently, he was treated with 5 days of intravenous methylprednisolone followed by an oral prednisone taper over 10 weeks, with improvement in symptoms. We report a unique case of neuromyelitis optica spectrum disorder (NMOSD) following treatment with ICIs. To our best knowledge, this is the third reported case in English literature of NMOSD following ICI therapy and the first reported case of NMOSD caused by ICI treatment in uveal melanoma.

引用

页数：5

共 17 条

[1] Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets [J].

Basile, Maria Sofia ;

Mazzon, Emanuela ;

Fagone, Paolo ;

Longo, Antonio ;

Russo, Andrea ;

Fallico, Matteo ;

Bonfiglio, Vincenza ;

Nicoletti, Ferdinando ;

Avitabile, Teresio ;

Reibaldi, Michele .

FRONTIERS IN ONCOLOGY, 2019, 9

[2] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[3] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[4] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].

Herbst, Roy S. ;

Giaccone, Giuseppe ;

de Marinis, Filippo ;

Reinmuth, Niels ;

Vergnenegre, Alain ;

Barrios, Carlos H. ;

Morise, Masahiro ;

Felip, Enriqueta ;

Andric, Zoran ;

Geater, Sarayut ;

Ozguroglu, Mustafa ;

Zou, Wei ;

Sandler, Alan ;

Enquist, Ida ;

Komatsubara, Kimberly ;

Deng, Yu ;

Kuriki, Hiroshi ;

Wen, Xiaohui ;

McCleland, Mark ;

Mocci, Simonetta ;

Jassem, Jacek ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339

[5] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J-J ;

Rutkowski, P. ;

Lao, C. D. ;

Cowey, C. L. ;

Schadendorf, D. ;

Wagstaff, J. ;

Dummer, R. ;

Ferrucci, P. F. ;

Smylie, M. ;

Hogg, D. ;

Hill, A. ;

Marquez-Rodas, I. ;

Haanen, J. ;

Guidoboni, M. ;

Maio, M. ;

Schoffski, P. ;

Carlino, M. S. ;

Lebbe, C. ;

McArthur, G. ;

Ascierto, P. A. ;

Daniels, G. A. ;

Long, G. V. ;

Bastholt, L. ;

Rizzo, J. I. ;

Balogh, A. ;

Moshyk, A. ;

Hodi, F. S. ;

Wolchok, J. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546

[6] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[7] Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report [J].

Narumi, Yoshitsugu ;

Yoshida, Ryohei ;

Minami, Yoshinori ;

Yamamoto, Yasushi ;

Takeguchi, Shiori ;

Kano, Kohei ;

Takahashi, Kae ;

Saito, Tsukasa ;

Sawada, Jun ;

Terui, Hiroya ;

Katayama, Takayuki ;

Sasaki, Takaaki ;

Ohsaki, Yoshinobu .

BMC CANCER, 2018, 18

[8] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[9] First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Ciuleanu, Tudor-Eliade ;

Cobo, Manuel ;

Schenker, Michael ;

Zurawski, Bogdan ;

Menezes, Juliana ;

Richardet, Eduardo ;

Bennouna, Jaafar ;

Felip, Enriqueta ;

Juan-Vidal, Oscar ;

Alexandru, Aurelia ;

Sakai, Hiroshi ;

Lingua, Alejo ;

Salman, Pamela ;

Souquet, Pierre-Jean ;

De Marchi, Pedro ;

Martin, Claudio ;

Perol, Maurice ;

Scherpereel, Arnaud ;

Lu, Shue ;

John, Thomas ;

Carbone, David P. ;

Meadows-Shropshire, Stephanie ;

Agrawal, Shruti ;

Oukessou, Abderrahim ;

Yan, Jinchun ;

Reck, Martin .

LANCET ONCOLOGY, 2021, 22 (02) :198-211

[10] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

← 1 2 →